ATHE vs. IPHA, GLSI, MGNX, GNLX, CKPT, CRGX, VXRT, ADAP, CDTX, and IFRX
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Innate Pharma (IPHA), Greenwich LifeSciences (GLSI), MacroGenics (MGNX), Genelux (GNLX), Checkpoint Therapeutics (CKPT), CARGO Therapeutics (CRGX), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), Cidara Therapeutics (CDTX), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry.
Alterity Therapeutics vs.
Alterity Therapeutics (NASDAQ:ATHE) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
In the previous week, Innate Pharma had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for Innate Pharma and 0 mentions for Alterity Therapeutics. Innate Pharma's average media sentiment score of 1.21 beat Alterity Therapeutics' score of 0.00 indicating that Innate Pharma is being referred to more favorably in the news media.
Innate Pharma has higher revenue and earnings than Alterity Therapeutics.
Alterity Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Alterity Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 96.08%. Innate Pharma has a consensus target price of $11.50, suggesting a potential upside of 413.39%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than Alterity Therapeutics.
Innate Pharma received 41 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 62.50% of users gave Alterity Therapeutics an outperform vote while only 58.97% of users gave Innate Pharma an outperform vote.
2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Innate Pharma beats Alterity Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATHE) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ATHE Stock Alerts